Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Danaher reported $6.54 billion in revenue for Q4 2024, a year-over-year increase of 2.1$6.46 billion [1] - The EPS for the quarter was $2.14, slightly below the consensus estimate of$2.17, resulting in an EPS surprise of -1.38% [1] Financial Performance Metrics - Organic sales growth was 1%, outperforming the four-analyst average estimate of -1.1% [4] - Total sales in Diagnostics reached $2.64 billion, exceeding the average estimate of$2.56 billion, but reflecting a year-over-year decline of -2.9% [4] - Life Sciences sales totaled $2.03 billion, surpassing the average estimate of$1.97 billion, with a year-over-year increase of +5.3% [4] - Biotechnology sales were reported at $1.87 billion, matching the average estimate, and showing a year-over-year growth of +6.3$376 million, exceeding the average estimate of $294.50 million [4] - Operating profit in Biotechnology was$508 million, slightly below the average estimate of $516.79 million [4] - Diagnostics operating profit was$624 million, compared to the average estimate of $792.33 million, indicating a significant shortfall [4] - Other operating profit was reported at -$83 million, worse than the average estimate of -$77.29 million [4] Stock Performance - Danaher's shares returned +8% over the past month, outperforming the Zacks S&P 500 composite's +1.7% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near term [3]